摘 要：散发性肾透明细胞癌中存在凡黑普尔-林道基因的突变，肾癌细胞的生长主要依赖血管内皮生长因子（VEGF），因此，以VEGF为靶点的药物广泛应用于肾癌的临床治疗。重组性单克隆抗体（如贝伐单抗）和与VEGF受体相结合的小分子抑制剂（如舒尼替尼、索拉非尼、阿西替尼、帕唑帕尼、瓦他拉尼）临床疗效已得到了验证，表现出较高的应答率、无进展生存时间的延长并提高了肾癌患者总生存率。就VEGF抑制剂的作用靶点、机制、治疗后患者敏感性以及临床试验等做一简要综述，为抗肿瘤药物研发提供思路。

Abstract：Von hippel-lindau gene mutation is very common in sporadic renal cell carcinoma，and vascular endothelial growth factor（VEGF）plays an important role in the growth of cancer cells．Therefore，VEGF-targeted drugs have been widely used in clinic treatment of renal cell carcinoma．Many VEGF-targeted drugs have been proved good therapeutic effects，including recombinant monoclonal antibodies（such as Bevacizumab）and small-molecule inhibitors that bind with VEGF receptors（such as Sunitinib，Sorafenib，Axitinib，Pazopanib，and Vatalanib）．Those medicines prolong the progression-free survival（PFS）and increase total survival rate of patients with renal cell carcinoma．This paper reviews the target site，function mechanism，patient sensitivity and clinic test of VEGF-targeted drugs，so as to provide certain help for the research and development of anti-tumor drugs．